Synergistic Targeting of Cell Membrane, Cytoplasm, and Nucleus of Cancer Cells Using Rod-Shaped Nanoparticles

被引:96
作者
Barua, Sutapa [1 ]
Mitragotri, Samir [1 ]
机构
[1] Univ Calif Santa Barbara, Dept Chem Engn, Ctr Bioengn, Santa Barbara, CA 93106 USA
基金
美国国家科学基金会;
关键词
camptothecin; herceptin; doxorubicin; nanoparticle; shape; synergistic; morphology; METASTATIC BREAST-CANCER; PACLITAXEL-LOADED NANOPARTICLES; RECEPTOR-MEDIATED ENDOCYTOSIS; TOPOISOMERASE-I; INTRACELLULAR DELIVERY; MONOCLONAL-ANTIBODY; 1ST-LINE TREATMENT; ANTITUMOR-ACTIVITY; CARBON NANOTUBES; TRASTUZUMAB;
D O I
10.1021/nn403913k
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Design of carriers for effective delivery and targeting of drugs to cellular and subcellular compartments is an unmet need in medicine. Here, we report pure drug nanoparticles comprising camptothecin ((PT), trastuzumab (TTZ), and doxorubicin (DOX) to enable cell-specific interactions, subcellular accumulation, and growth inhibition of breast cancer cells. CPT is formulated in the form of nanorods which are coated with TTZ. DOX is encapsulated in the TTZ corona around the CPT nanoparticle. Our results show that TTZ/DOX-coated CPT nanorods exhibit cell-specific internalization in BT-474 breast cancer cells, after which TTZ is recycled to the plasma membrane, leaving CPT nanorods in the perinuclear region and delivering DOX into the nucleus of the cells. The effects of CPT-TTZ-DOX nanoparticles on growth inhibition are synergistic (combination index = 0.17 +/- 0.03) showing 10-10000-fold lower inhibitory concentrations (IC50) compared to those of individual drugs. The design of antibody-targeted pure drug nanoparticles offers a promising design strategy to facilitate intracellular delivery and therapeutic efficiency of anticancer drugs.
引用
收藏
页码:9558 / 9570
页数:13
相关论文
共 79 条
  • [1] Endocytosis and sorting of ErbB2 and the site of action of cancer therapeutics trastuzumab and geldanamycin
    Austin, CD
    De Mazière, AM
    Pisacane, PI
    van Dijk, SM
    Eigenbrot, C
    Sliwkowski, MX
    Klumperman, J
    Scheller, RH
    [J]. MOLECULAR BIOLOGY OF THE CELL, 2004, 15 (12) : 5268 - 5282
  • [2] Quantum dot - Aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer
    Bagalkot, Vaishali
    Zhang, Liangfang
    Levy-Nissenbaum, Etgar
    Jon, Sangyong
    Kantoff, Philip W.
    Langer, Robert
    Farokhzad, Omid C.
    [J]. NANO LETTERS, 2007, 7 (10) : 3065 - 3070
  • [3] Bang YJ, 2010, LANCET, V376, P1302
  • [4] Particle shape enhances specificity of antibody-displaying nanoparticles
    Barua, Sutapa
    Yoo, Jin-Wook
    Kolhar, Poornima
    Wakankar, Aditya
    Gokarn, Yatin R.
    Mitragotri, Samir
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (09) : 3270 - 3275
  • [5] ADRIAMYCIN - NEW ANTICANCER DRUG WITH SIGNIFICANT CLINICAL ACTIVITY
    BLUM, RH
    CARTER, SK
    [J]. ANNALS OF INTERNAL MEDICINE, 1974, 80 (02) : 249 - 259
  • [6] BODLEY A, 1989, CANCER RES, V49, P5969
  • [7] Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) -Positive Breast Cancer After Prior HER2-Directed Therapy
    Burris, Howard A., III
    Rugo, Hope S.
    Vukelja, Svetislava J.
    Vogel, Charles L.
    Borson, Rachel A.
    Limentani, Steven
    Tan-Chiu, Elizabeth
    Krop, Ian E.
    Michaelson, Richard A.
    Girish, Sandhya
    Amler, Lukas
    Zheng, Maoxia
    Chu, Yu-Waye
    Klencke, Barbara
    O'Shaughnessy, Joyce A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04) : 398 - 405
  • [8] Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: A pilot study
    Burstein, HJ
    Harris, LN
    Gelman, R
    Lester, SC
    Nunes, RA
    Kaelin, CM
    Parker, LM
    Ellisen, LW
    Kuter, I
    Gadd, MA
    Christian, RL
    Kennedy, PR
    Borges, VF
    Bunnell, CA
    Younger, J
    Smith, BL
    Winer, EP
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (01) : 46 - 53
  • [9] Quantitative Investigation of Compartmentalized Dynamics of ErbB2 Targeting Gold Nanorods in Live Cells by Single Molecule Spectroscopy
    Chen, Jiji
    Irudayaraj, Joseph
    [J]. ACS NANO, 2009, 3 (12) : 4071 - 4079
  • [10] Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles
    Choi, Chung Hang J.
    Alabi, Christopher A.
    Webster, Paul
    Davis, Mark E.
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2010, 107 (03) : 1235 - 1240